Home > Search Clinical Trials > Gastrointestinal (Stomach, Bowel, Etc.)
Clinical Trials: Gastrointestinal (Stomach, Bowel, Etc.)
IRB No. 16-170J-1 (Dr. Thomas Devers, PI): Microbiome analysis in C. Difficile Infection and Fecal Microbiota Transplant
Clostridium difficile is a bacteria which causes life-threatening inflammation of the colon, infection and diarrhea. C. difficile infection (CDI) is difficult to treat and is associated with a high rate of antibiotic failure. Recurrence of CDI is common and occurs in 30 - 65% of patients. The recent development of Fecal Microbiota Transplant (FMT) stool transplant therapy, that involves the infusion of stool from a healthy donor into the infected colon, has demonstrated effectiveness in curing CDI. This research study will involve close collaboration between gastroenterologists at UConn Health and Microbial Genomics at the Jackson Laboratory for Genomic Medicine (JAX-GM). The specific aims of this project include identification and analysis of specific gut bacteria using genomic microbial analysis techniques in patients with C. Difficile infection pre- and post- stool transplant and of the healthy stool transplant donor. Through these analyses, we will gain a better understanding of the changes to the intestinal bacterial communities in Clostridium Difficile infection before and after FMT. This research may eventually lead to novel therapies by identification and isolation of intestinal bacteria associated with both infection and cure of CDI.
IRB No. 17-068-2 (Dr. Jose Orellana, PI): Vitamin B12 Deficiency and H. pylori Infection
In this study we aim to determine if there is a link between vitamin B12 deficiency/macrocytic anemia and H. pylori infection in the patients at the UConn Southington Primary Care Office. This will be done in order to discern if H. pylori testing would be efficacious for individuals at this office found to be anemic or deficient in vitamin B. In order to do this we will conduct a retrospective chart review with the goal of analyzing data for approximately 100 patients. We will use billing codes to identify patients with diagnoses of vitamin B12 deficiency or megaloblastic anemia and exclude those with diagnoses of pernicious anemia. Patient identifying information will not be included in data collection. Statistical analysis will be performed to determine if there is a statistically significant difference between patients with vitamin B12 deficiency and those with both vitamin B12 deficiency and H. pylori infection.